← Back to search
MICROBIOTIX, INC.
WORCESTER, MA, 01605
UnclaimedClaim this profile (free)
Prime contracting experience
3 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. | — | $7,263,391 | Aug 26, 2026 | Jul 1, 2020 – Jul 28, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES. | — | $8,795,790 | Aug 21, 2026 | Nov 1, 2022 – Mar 1, 2028 |
| Prime | Department of Defense Defense Contract Management Agency | DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES) | — | $2,554,224 | Dec 4, 2024 | Dec 15, 2017 – Dec 14, 2018 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | THE STEADY RISE IN THE PREVALENCE OF MULTI-DRUG RESISTANT (MDR) GRAM-NEGATIVE PATHOGENS IS A SILENT PANDEMIC THAT POSES SIGNIFICANT CHALLENGES TO THE HEALTHCARE SYSTEM BUT HAS NOT GAINED WIDESPREAD RECOGNITION OUTSIDE OF THE RESEARCH COMMUNITY. AT LEAST 2.8 MILLION PEOPLE IN THE US ACQUIRE SERIOUS INFECTIONS CAUSED BY BACTERIA THAT ARE RESISTANT TO ONE OR MORE OF THE ANTIBIOTICS CURRENTLY APPROVED TO TREAT THOSE INFECTIONS, RESULTING IN AT LEAST 35,000 DEATHS IN THE U.S. EACH YEAR DUE TO TREATMENT FAILURES. INDEED, THERE ARE PATHOGENS RESISTANT TO ALL ANTIBIOTICS, FORCING USE OF OLDER DRUGS WITH KNOWN TOXICITIES (E.G., COLISTIN). CLEARLY, THERE IS AN IMMEDIATE CLINICAL NEED FOR NOVEL THERAPEUTIC MODALITIES FOR TREATING INFECTIONS CAUSED BY MDR BACTERIAL PATHOGENS. TO ADDRESS THIS NEED, WE HAVE DEVELOPED AN OPTIMIZED SERIES OF INHIBITORS TARGETING THE P. AERUGINOSA T3SS, BASED ON A NOVEL, SMALL MOLECULE PHENOXYACETAMIDE (PHA) SCAFFOLD. THE ADVANCED LEAD COMPOUND, MBX-5452, HAS DEMONSTRATED EFFICACY IN MULTIPLE MURINE INFECTION MODELS IN A CLINICALLY ACCEPTABLE FORMULATION AND WITH ADMINISTRATION BEGINNING 1 HR POST INFECTION. MBX-5452 REDUCED THE NUMBER OF CFUS AND EXTENDED SURVIVAL TIME WHEN USED EITHER AS A STANDALONE THERAPEUTIC OR IN COMBINATION WITH THE ANTIPSEUDOMONAL ANTIBIOTIC MEROPENEM (I.E., A SUB-EFFICACIOUS MEROPENEM DOSE TO GENERATE AN EXPERIMENTAL ASSAY WINDOW FOR SYNERGY). IN ADDITION, MBX-5452 EXHIBITS A GOOD IN VITRO AND IN VIVO SAFETY PROFILE AND FAVORABLE PHARMACOKINETIC PARAMETERS IN MICE AND RATS. THE WORK PACKAGE PROPOSED HERE WILL PROVIDE ADDITIONAL DATA TO DE-RISK THE PROGRAM FOR IND-ENABLING STUDIES. 4500004548 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $45,233 | Jan 17, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THIS PROGRAM SEEKS TO OPTIMIZE AND DEVELOP A VALIDATED HIT SERIES OF BACTERIAL TRANS-TRANSLATION INHIBITORS INTO A BROAD-SPECTRUM ANTIBIOTIC FOR USE AS A SINGLE DOSE ORAL THERAPY TO TREAT INFECTIONS CAUSED BY MDR NEISSERIA GONORRHOEAE (NG). THE LIMITED NUMBER OF EFFICACIOUS THERAPIES FOR NG INFECTION, THE ACCELERATING EMERGENCE OF MULTI-DRUG RESISTANCE, AND THE LIMITED DEVELOPMENT PIPELINE OF NEW THERAPEUTICS HIGHLIGHT THE DIRE NEED FOR NEW STRATEGIES.
BACTERIAL TRANSLATION IS PLAGUED BY TRANSCRIPTION ERRORS, MRNA DAMAGE, AND TRANSLATIONAL FRAMESHIFTS THAT RESULT IN LOSS OF THE STOP CODON AND FORMATION OF A NON-STOP RIBOSOME COMPLEX, PREVENTING RELEASE OF THE PROTEIN PRODUCTS AND INHIBITING FURTHER TRANSLATION. ESTIMATED TO OCCUR > 5 TIMES/RIBOSOME/REPLICATION CYCLE, RESCUE OF NON-STOP RIBOSOME COMPLEXES IS AN ESSENTIAL PROCESS IN BACTERIA. THE PRIMARY SYSTEM FOR NON-STOP RIBOSOME RESCUE IN BACTERIA IS TRANS-TRANSLATION, COMPRISED OF TMRNA AND SMPB WORKING IN CONCERT WITH ELONGATION FACTOR TU (EF-TU) TO RESTORE PROTEIN SYNTHESIS, EJECT THE DAMAGED MRNA, AND TAG THE NASCENT PROTEIN FOR PROTEOLYSIS. GENES ASSOCIATED WITH TRANS-TRANSLATION HAVE BEEN FOUND IN EVERY BACTERIAL GENOME SEQUENCED TO DATE; MUTATIONS IN THESE COMPONENTS AFFECT VIABILITY OR VIRULENCE IN A WIDE VARIETY OF BACTERIA, AND ARE ESSENTIAL IN NG. THE TRANS-TRANSLATION PATHWAY IS NOT FOUND IN ANIMALS, ALLOWING INHIBITORS OF THIS PATHWAY TO EXERT A SPECIFIC EFFECT ON BACTERIA IN THE PRESENCE OF HOST CELLS.
IN PRELIMINARY STUDIES, WE IDENTIFIED SMALL MOLECULES THAT INHIBIT TRANS-TRANSLATION, ACTING AS POTENT ANTIMICROBIALS AGAINST A RANGE OF PATHOGENS, INCLUDING NG, WITH A KEY ANALOG INHIBITING >95% OF TESTED MDR NG STRAINS AT LOW CONCENTRATIONS (MIC90 = 0.27 ÂÂΜG/ML). MECHANISTIC STUDIES REVEALED THAT INHIBITION OF TRANS-TRANSLATION OCCURS THROUGH COMPOUND BINDING TO ELONGATION FACTOR TU (AN ESSENTIAL COMPONENT OF PROTEIN SYNTHESIS AND TRANS-TRANSLATION), SELECTIVELY INHIBITING TRANS-TRANSLATION OVER TRANSLATION. PRELIMINARY EVALUATION OF THESE COMPOUNDS DEMONSTRATED RESPONSIVE STRUCTURE-ACTIVITY RELATIONSHIPS (SAR), A CLEAN TOXICITY PROFILE, AND HIGHLY SIGNIFICANT, DOSE-DEPENDENT EFFICACY IN A MURINE MODEL OF UROGENITAL NG INFECTION AFTER A SINGLE ORAL DOSE WITH AN ADVANCED HIT COMPOUND.
THE OBJECTIVE OF THIS CARB-X-FUNDED PROGRAM IS TO PROGRESS THESE COMPOUNDS THROUGH HIT-TO-LEAD, LEAD OPTIMIZATION, PRECLINICAL STUDIES, AND PHASE 1 CLINICAL TRIALS. SUBSEQUENT EFFORTS WILL FOCUS ON PHASE 2/3 CLINICAL TRIALS AND SUBMISSION TO REGULATORY AUTHORITIES FOR MARKETING APPROVAL OF THIS NEW CLASS OF ANTIBIOTICS OPERATING THROUGH A FUNDAMENTALLY NEW ANTIBACTERIAL MECHANISM. 4500004386 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $286,609 | Oct 21, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.